Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Adjuvanticity, which is the ability of neoplastic cells to deliver danger signals, is critical for the host immune system to mount spontaneous and therapy-driven anticancer immune responses. One of such signals, i.e., the exposure of calreticulin (CALR) on the membrane of malignant cells experiencing endoplasmic reticulum (ER) stress, is well known for its role in the activation of immune responses to dying cancer cells. However, the potential impact of CALR on the immune contexture of primary and metastatic high-grade serous carcinomas (HGSCs) and its prognostic value for patients with HGSC remains unclear. METHOD: We harnessed a retrospective cohort of primary (no = 152) and metastatic (no = 74) tumor samples from HGSC patients to investigate the CALR expression in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on second prospective cohort of freshly resected HGSC samples. In silico analysis of publicly available RNA expression data from 302 HGSC samples was used as a confirmatory approach. RESULTS: 1 polarization and cytotoxic activity that enables superior clinical benefits. CONCLUSIONS: Our data indicate that CALR levels in primary and metastatic HGSC samples have robust prognostic value linked to the activation of clinically-relevant innate and adaptive anticancer immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the ability of malignant cells to proficiently expose the endoplasmic reticulum (ER) protein calreticulin (CALR) on their surface as an adjuvantlike signal has been associated with superior disease outcome in patients with acute myeloid leukemia (Truxova et al., 2020) and ovarian carcinoma (Kasikova et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Kasikova et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.-H., Pagès, F., Trajanoski, Z., & Galon, J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp101 · Cited by 6,280
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citation
Cited by
Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citationImmunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Self-citationDetection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Self-citationFucikova, J., Spisek, R., Kroemer, G., & Galluzzi, L. (2021) · Cell Research · doi:10.1038/s41422-020-0383-9 · Cited by 400
Self-citationAssociation of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Kalantari, M., Mohammadinejad, R., Javaheri, T., & Sethi, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114002 · Cited by 248
“Chemotherapy is still one of the most common modalities used in cancer therapy [30].”
Metadata
- Authors
- Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., Rob, L., Presl, J., Kostun, J., Cremer, I., Ryska, A., Kroemer, G., Galluzzi, L., Spisek, R., & Fucikova, J.
- Affiliations
- Sotio (Czechia) (CZ)
- Inserm (FR)
- Karolinska University Hospital (SE)
- Yale University (US)
- Charles University (CZ)
- Corresponding author
- Fucikova, Jitka
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-11-20
- Volume
- 7
- Issue
- 1
- Pages
- 312-312
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6868694
- OpenAlex
- W2990968959
- Cited by
- 79
- References
- 44
- Citations by year
- 2026: 10 · 2025: 5 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 15 · 2020: 14
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Defense (#BC180476P1)
- Weill Cornell Medical College
- European Regional Development Fund (EF16_013/0001674)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- calreticulin, high-grade serous carcinoma, ovarian carcinoma, adjuvant effect, endoplasmic reticulum stress, tumor microenvironment, antitumor immunity, prognostic factors, metastatic ovarian cancer, innate immunity, adaptive immunity, cytotoxic T lymphocytes
- MeSH terms
- RNA-Seq, Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Ovarian Neoplasms, Prognosis, Calreticulin, Tumor Microenvironment, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. https://app.cochat.ai/papers/10.1186/s40425-019-0781-z
- The paper
- Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., Rob, L., Presl, J., Kostun, J., Cremer, I., Ryska, A., Kroemer, G., Galluzzi, L., Spisek, R., & Fucikova, J. (2019). Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0781-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.